GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2020-05-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 608
- Registration Number
- NCT02637856
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center; Department of Neurology, Columbus, Ohio, United States
🇺🇸Allegheny Neurological Associates, Pittsburgh, Pennsylvania, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2015-12-14
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT02629744
A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults
- First Posted Date
- 2015-12-07
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT02623322
- Locations
- 🇺🇸
Oceane7 Clinical Research, Miami, Florida, United States
🇺🇸North Alabama Research Center LLC, Athens, Alabama, United States
🇺🇸Lalla-Reddy Medical Corporation, Fountain Valley, California, United States
Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02621957
A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State
- Conditions
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02608034
- Locations
- 🇮🇱
Hadassah Ein Karem Hospital; Oncology Dept, Jerusalem, Israel
🇰🇷Samsung Medical Center; Gastroenterology, Seoul, Korea, Republic of
🇷🇺FSBSI "N. N. Blokhin Russian Cancer Research Center", Moscow, Russian Federation
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Healthy Volunteers
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2018-03-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02596399
- Locations
- 🇺🇸
PRA International Clinical Pharmacology Center (EDS US Clinic), Lenexa, Kansas, United States
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT02593331
- Locations
- 🇺🇸
Profil Institute for Clinical Research Inc., Chula Vista, California, United States
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
- Conditions
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT02589717
A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy
- First Posted Date
- 2015-10-07
- Last Posted Date
- 2021-04-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT02569801
- Locations
- 🇺🇸
Florida Cancer Specialists-Broadway, Fort Myers, Fort Myers, Florida, United States
🇺🇸Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building), Saint Petersburg, Florida, United States
🇺🇸The Center for Cancer and Blood Disorders - Fort Worth, Fort Worth, Texas, United States
Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects
- First Posted Date
- 2015-08-31
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02536391